Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 62170 record(s)

Req # A-2023-000630

Adverse Drug Reactions (ADRs) for AMPHETAMINE ASPARTATE MONOHYDRATE/AMPHETAMINE SULFATE/DEXTROAMPHETAMINE SACCHARATE/ DEXTROAMPHETAMINE SULFATE. Report numbers: 001040668, E2B_06395423. ADRs for MESALAMINE. Report numbers: E2B_06369931, E2B_06341301, E2B_06366079, E2B_06371506. ADRs for VYVANSE. Report numbers: 001038506, 001049884, 001040486, 001042502.

Organization: Health Canada

103 page(s)
February 2024

Req # A-2023-000642

Adverse Drug Reactions (ADRs). Report numbers: E2B_06380669, E2B_06391938, E2B_06347544, E2B_06389442, 001039604, 001039011, E2B_06359710, E2B_06400511, E2B_06353100, E2B_06228427.

Organization: Health Canada

463 page(s)
February 2024

Req # A-2023-000704

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105579-25.

Organization: Health Canada

26 page(s)
February 2024

Req # A-2023-000742

Adverse Drug Reactions (ADRs). Report numbers: E2B_06460600, E2B_06419945, 001046719, 001046738, 001046744, E2B_06416439.

Organization: Health Canada

51 page(s)
February 2024

Req # A-2023-000760

Adverse Drug Reactions (ADRs). Report numbers: 000978141; 001038383; 001038384.

Organization: Health Canada

57 page(s)
February 2024

Req # A-2023-000783

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106469-662.

Organization: Health Canada

5 page(s)
February 2024

Req # A-2023-000786

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106698-677.

Organization: Health Canada

4 page(s)
February 2024

Req # A-2023-000845

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105825-209.

Organization: Health Canada

11 page(s)
February 2024

Req # A-2023-000851

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106698-677.

Organization: Health Canada

4 page(s)
February 2024

Req # A-2023-000854

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-106499-859.

Organization: Health Canada

25 page(s)
February 2024
Date modified: